Epigenetic Control of Mucosal IRF1/IFN-III Antiviral Response by Enhancer-like Promoter and its Coding lncRNA
增强子样启动子及其编码lncRNA对粘膜IRF1/IFN-III抗病毒反应的表观遗传控制
基本信息
- 批准号:10373575
- 负责人:
- 金额:$ 25.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-24 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAddressAdultAffinity ChromatographyAgeAllergensAllergicAntiviral AgentsAntiviral ResponseBindingBiological AssayCRISPR interferenceCRISPR/Cas technologyCellsChildChromatinChromatin LoopChromatin StructureChronicCodeComplexDNA Polymerase IIDetectionEnhancersEpigenetic ProcessEpithelialEpithelial CellsEuchromatinExcisionExhibitsExtrinsic asthmaFeedbackGene ActivationGenesGenetic TranscriptionGenomeGoalsHost DefenseHumanIRF1 geneIRF3 geneImmunityImpairmentInflammationInflammatory ResponseInterferonsLiteratureLocationMeasuresMediatingMediator of activation proteinMesenchymalMicrobiologyModificationMolecular ConformationMucosal ImmunityMucous MembraneNatural ImmunityNatureNuclearPathway interactionsPatientsPatternPhosphorylationPlayPoly I-CPositioning AttributeProductionProteomicsRNARecurrenceReportingRespiratory Syncytial Virus InfectionsRespiratory SystemRespiratory syncytial virusRhinovirusRibonucleoproteinsRoleRunningSerotypingSignal TransductionTechniquesTestingTranscription ElongationTranscription RepressorUntranslated RNAUpstream EnhancerViralViral Respiratory Tract InfectionVirusVirus DiseasesVirus ReplicationWorkairway epitheliumairway remodelingallergic airway diseaseantiviral immunityasthma exacerbationasthmaticbasechromatin immunoprecipitationchromosome conformation capturecytokinedesignexperimental studygenome editinggenome-widein vivoloss of functionnegative elongation factornext generation sequencingnovelpathogenic viruspreventprogramspromoterrecruitrespiratory infection virusresponsetranscription factor
项目摘要
PROJECT SUMMARY/ABSTRACT
Viral respiratory infections are the most common causes of exacerbations in children and adults with allergic
asthma. Because pathogenic viruses initially replicate in the mucosa, the epithelium plays a key role in mounting
innate inflammatory responses. Upon detection of replicating virus, the interferon regulatory factor-1 (IRF1) is
highly induced, producing type III interferon (IFNL), a key mediator of mucosal innate immunity. We have
discovered that the IRF1 gene is regulated by a previously unknown upstream enhancer-like promoter
(Epromoter) whose activity is induced by viral infection and silenced by cell-state changes produced by allergic
asthma. In preliminary studies, we find that the potential IRF1 Epromoter displays enhancer activity of virus-
inducible IRF1 transcription in primary human small airway epithelial cells (hSAECs). The IRF1 Epromoter
transcribes an unannotated IRF1 antisense upstream (AU) long noncoding RNA, IRF1-AU. Expression of the
5.8 kb IRF1-AU is inducible by viral infection and changed by mesenchymal transition. In this R21 application,
we will investigate the hypothesis that IRF1 Epromoter is a cell-state regulated epigenetic regulator of
mucosal IRF1-IFNL response. We will dissect the relative contributions of IRF1 Epromoter as the enhancer of
IRF1 and the promoter of IRF1-AU on viral inducible IRF1-IFNL response in two hypotheses: 1. The IRF1-
Epromoter maintains the IRF1-IFNL pathway in a highly inducible state by direct (looping) interactions
with the proximal IRF1 promoter. We will test the presence of direct looping interactions by chromatin
conformation capture (3C/4C) studies using KRAB-dCas9 silencing or CRISPR/Cas9 excision of IRF1-
Epromoter. We will measure effects on the accessibility of IRF1 proximal promoter by quantifying binding of
IRF3 and NFκB transcription factors, recruitment of transcriptional elongation machinery and accumulation of
euchromatin marks by chromatin immunoprecipitation (XChIP) assays. Studies are also designed to examine
the effects of cell-state transitions. 2. The inducible IRF1-AU is a ribonucleo-protein complex that facilitates
transcriptional elongation of IRF1. We will modulate IRF1-AU using gain- and loss-of-function approaches
and challenge wild type and mesenchymal transitioned hSAECs to rhinovirus. Changes in chromatin looping,
recruitment of IRF3/NFκB and transcriptional elongation will be measured. Using established affinity purification
(AP)-LC-MS, we will identify the composition of the IRF1-AU ribonucleoprotein complex. We are uniquely
qualified to conduct these studies based on our track record of CRISPR/Cas9 genome targeting, XChIP and
discovery proteomics. Upon completion of these studies, we will have elucidated a novel mechanism for
epigenetic control of mucosal IRF1-IFNL production that will position us for a R01 level project. This project
would establish the role of the IRF1 Epromoter and IRF1-AU in innate anti-viral immunity in vivo, and to identify
how cell-state changes produced by allergic asthma modify its composition and function.
项目摘要/摘要
呼吸道病毒感染是导致儿童和成人过敏性疾病恶化的最常见原因
哮喘。由于致病病毒最初在粘膜中复制,因此上皮在安装过程中起关键作用。
先天的炎症反应。在检测到复制病毒时,干扰素调节因子-1(IRF1)是
高度诱导产生III型干扰素(IFNL),这是粘膜天然免疫的关键介质。我们有
发现IRF1基因受一个未知的上游增强子样启动子调控
(启动子),其活性由病毒感染诱导,并因过敏引起的细胞状态变化而沉默
哮喘。在初步研究中,我们发现潜在的IRF1启动子具有病毒的增强活性-
原代人小气道上皮细胞(HSAECs)可诱导IRF1转录。IRF1启动子
转录一个未注释的IRF1反义上游(AU)长的非编码RNA,IRF1-AU。的表达
5.8kb的IRF1-AU可被病毒感染诱导,并可通过间充质转化而改变。在此R21应用程序中,
我们将研究IRF1 E启动子是细胞状态调节的表观遗传调节因子的假设。
黏膜IRF1-IFNL反应。我们将剖析IRF1启动子作为基因增强子的相对贡献。
IRF1和IRF1-AU启动子对病毒诱导的IRF1-IFNL反应的两个假设:1.IRF1-
E启动子通过直接(环)相互作用将IRF1-IFNL途径维持在高度可诱导的状态
与IRF1启动子近端连接。我们将通过染色质测试直接循环相互作用的存在
使用KRAB-dCas9沉默或CRISPR/Cas9切除IRF1-的构象捕获(3C/4C)研究
发起人。我们将通过量化IRF1近端启动子的结合来衡量对IRF1近端启动子可及性的影响
IRF3和NFκB转录因子,转录延长机制的招募和转录延长机制的积累
常染色质标记采用染色质免疫沉淀(XChIP)法。研究的目的也是为了检查
细胞状态转换的影响。2.可诱导的IRF1-AU是一种核糖核蛋白复合体,可促进
IRF1的转录延伸。我们将使用增益和损耗函数方法来调制IRF1-AU
攻击野生型和间充质向鼻病毒转化的hSAECs。染色质环路的变化,
将测量irf3/nfκB的招募和转录延伸。使用已建立的亲和纯化
(AP)-LC-MS,我们将确定IRF1-AU核糖核蛋白复合体的组成。我们独一无二
有资格根据我们在CRISPR/Cas9基因组靶向、XChIP和
发现蛋白质组学。在这些研究完成后,我们将阐明一种新的机制,以
对粘膜IRF1-IFNL生产的表观遗传控制,这将使我们为R01级项目定位。这个项目
将确定IRF1启动子和IRF1-AU在体内先天抗病毒免疫中的作用,并鉴定
过敏性哮喘产生的细胞状态变化如何改变其组成和功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Allan R. Brasier其他文献
The NF-κB regulatory network
- DOI:
10.1385/ct:6:2:111 - 发表时间:
2006-06-01 - 期刊:
- 影响因子:3.700
- 作者:
Allan R. Brasier - 通讯作者:
Allan R. Brasier
11: BRD4-MK2 SIGNALING: TARGET FOR CROHN'S DISEASE-ASSOCIATED FIBROSIS.
- DOI:
10.1016/s0016-5085(22)60011-8 - 发表时间:
2022-05-01 - 期刊:
- 影响因子:
- 作者:
Marina Chulkina;Steven B. McAninch;Yi Li;Walter Koltun;Gregory S. Yochum;Bing Tian;Jia Zhou;Ellen J. Beswick;Allan R. Brasier;Iryna V. Pinchuk - 通讯作者:
Iryna V. Pinchuk
33 NOVEL SMALL MOLECULE BRD4 INHIBITORS SUPPRESS COLONIC INFLAMMATION IN MOUSE MODELS OF INFLAMMATORY BOWEL DISEASE
- DOI:
10.1016/s0016-5085(21)00770-8 - 发表时间:
2021-05-01 - 期刊:
- 影响因子:
- 作者:
Zhiqing Liu;Gabriela Uribe;Yi Li;Pingyuan Wang;Haiying Chen;Yingzi Cong;Allan R. Brasier;Iryna V. Pinchuk;Jia Zhou;Bing Tian - 通讯作者:
Bing Tian
Transcriptional regulation of angiotensinogen gene expression.
血管紧张素原基因表达的转录调控。
- DOI:
- 发表时间:
1999 - 期刊:
- 影响因子:0
- 作者:
Allan R. Brasier;Youqi Han;C. T. Sherman - 通讯作者:
C. T. Sherman
Pollen-induced oxidative DNA damage response regulates miRNAs controlling allergic inflammation
- DOI:
- 发表时间:
2017 - 期刊:
- 影响因子:
- 作者:
Leopoldo Aguilera-Aguirre;Wenging Hao;Lang Pan;Xiaoxue Li;Alfredo Saavedra-Molina;Attila Bacsi;Zsolt Radak;Sanjiv Sur;Allan R. Brasier;Xueqing Ba;Istvan Boldogh - 通讯作者:
Istvan Boldogh
Allan R. Brasier的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Allan R. Brasier', 18)}}的其他基金
Epigenetic Control of Mucosal IRF1/IFN-III Antiviral Response by Enhancer-like Promoter and its Coding lncRNA
增强子样启动子及其编码lncRNA对粘膜IRF1/IFN-III抗病毒反应的表观遗传控制
- 批准号:
10495267 - 财政年份:2021
- 资助金额:
$ 25.28万 - 项目类别:
Epigenetic Mechanism Reprogramming Mucosal Anti-viral Immunity in Allergic Asthma
过敏性哮喘粘膜抗病毒免疫的表观遗传机制重编程
- 批准号:
10553704 - 财政年份:2019
- 资助金额:
$ 25.28万 - 项目类别:
Epigenetic Mechanism Reprogramming Mucosal Anti-viral Immunity in Allergic Asthma
过敏性哮喘粘膜抗病毒免疫的表观遗传机制重编程
- 批准号:
10371977 - 财政年份:2019
- 资助金额:
$ 25.28万 - 项目类别:
Transcriptional Elongation in NF-kB Mediated Inflammation
NF-kB 介导的炎症中的转录延伸
- 批准号:
8710493 - 财政年份:2013
- 资助金额:
$ 25.28万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 25.28万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 25.28万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 25.28万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 25.28万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 25.28万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 25.28万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 25.28万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 25.28万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 25.28万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 25.28万 - 项目类别:
Research Grant